Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Jun 4, 2020 1:59 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

June 2, 2020

- Maralixibat-treated patients achieving serum bile acid control have five-year native liver survival after treatment. - Data demonstrate normalization and reductions of liver enzymes, reduced pruritus, and improved growth. - Data selected for oral presentation at the Digital International Liver

Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

May 29, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--May 29, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz , president and chief executive officer

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 11, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--May 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation Committee

Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates

May 7, 2020

- On track to begin rolling submission of NDA for maralixibat in Alagille Syndrome (ALGS) in third quarter 2020 - Cash, cash equivalents and investments balance of $166.1 million FOSTER CITY, Calif. --(BUSINESS WIRE)--May 7, 2020-- Mirum Pharmaceuticals, Inc.

Events

Jefferies 2020 Healthcare Conference

Jun 2, 2020 at 1:00 PM EDT

Listen to webcast

Raymond James 41st Annual Institutional Investors Conference

Mar 4, 2020 at 9:15 AM EST

Listen to webcast

Cowen 40th Annual Healthcare Conference

Mar 2, 2020 at 2:10 PM EST

Listen to webcast

Investor Relations

Investor Relations

Corporate Profile

Header Menu